Biotech Investors: Believing the Dream, Rewarding Phase III IPOs

Valuation Watch: our analysis of US biotech companies that have gone public in the 2003-04 window shows that having a late-stage development project offers private investors the best step-ups.

Few biotechnology firms without a late-stage or marketed product have gone public through the current 2003-2004 financing window. In fact, among the 28 biotech IPOs in the US during this time frame tracked in Windhover's Strategic Intelligence Systems, only two firms—Alnylam Pharmaceuticals Inc. (an Alnylam Holding Co. subsidiary) and Momenta Pharmaceuticals Inc. —braved the IPO waters without a clinical-stage project [See Deal]. Just two more, Anadys Pharmaceuticals Inc. and Memory Pharmaceuticals Corp. , were as far along as Phase I [See Deal]. [Note: we've excluded Momenta from this analysis: although it had no candidates in the clinic when it went public, it would be disingenuous to view the company as a preclinical-stage biotech. Its sugar sequencing technology will initially yield non-NME drug candidates more suitable to ANDAs—like its generic version of Sanofi-Aventis SA 's enoxaparin sodium (Lovenox).]

The markets' preference for biotech IPO candidates with late-stage products is well-known and is borne out in an analysis of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.